Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sarconeos - Biophytis

Drug Profile

Sarconeos - Biophytis

Alternative Names: BIO 101

Latest Information Update: 16 Oct 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biophytis
  • Class Antivirals; Obesity therapies; Small molecules
  • Mechanism of Action Proto-oncogene protein c-mas-1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Adult respiratory distress syndrome; COVID 2019 infections
  • Phase II Muscular atrophy
  • Phase I Duchenne muscular dystrophy
  • Preclinical Obesity

Most Recent Events

  • 16 Oct 2020 9305215: No Updates, info already covered
  • 18 Sep 2020 BIOPHYTIS plans the pivotal phase II/III MYODA-INT in Duchenne muscular dystrophy (In ambulant children) in Europe by the end of 2020
  • 01 Sep 2020 Phase-II/III clinical trials in Adult respiratory distress syndrome in Belgium (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top